• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Options

As Covid Threat Weakens, This Biotech Is Still Worth a Shot

Here's a way to trade Vir Biotechnology.
By BRET JENSEN
Mar 05, 2023 | 07:30 AM EST
Stocks quotes in this article: VIR, GSK, FLGT

Vir Biotechnology, Inc. (VIR)  is a biotech company facing the apparent winding down of the Covid crisis while sitting on a huge amount of net cash -- and with other projects in the pipeline. 

The company focuses on identifying the limitations of the immune system in its fight against specific pathogens and the vulnerabilities of those pathogens. Vir uses this information to develop way of treating infectious diseases. This small biotech has one approved Covid-19 therapy in collaboration with GlaxoSmithKline (GSK)  (with significantly declining revenue) called sotrovimab and four others in the clinic.

The company has benefited significantly from the fight against Covid, including receiving an upfront payment of $225 million as well as a $120 million equity investment from Glaxo in 2021. Unfortunately, this human neutralizing monoclonal antibody proved ineffective against new variants and has all but been discontinued from mass use. However, Covid-related revenues have allowed the company to build up a huge cash position.

Vir's balance sheet reflects cash and investments of $2.4 billion (as of year-end 2022) plus an additional $400 million or so anticipated from sotrovimab and other collaboration payments from GSK, meaning that it holds essentially around $20 a share in cash. The stock currently trades around $23 a share. The company also has been able to fund and advance the rest of its pipeline. These include a promising vaccine for influenza A that is in mid-stage development. It also has candidates to treat hepatitis B and D in mid-stage clinical study and a pre-clinical effort evaluating T cell candidates as a potential treatment for HIV.

All in all, Vir is a pretty compelling "sum of the parts" story at current trading levels. One we can enhance further by bringing down any potential entry at under the company's current net cash using a simple covered call strategy.

The company is somewhat reminiscent of last week's covered call trade idea for Fulgent Genetics (FLGT) . This diagnostic concern will see overall sales plunge in 2023 as its Covid testing revenue dries up as the pandemic ebbs. However, the company will see big growth from it core testing business and Fulgent was sitting on a huge cash hoard. This Tuesday, the company beat fourth quarter expectations and provided a nice boost in guidance for the coming fiscal year as well.

Option Strategy:

To establish an initial position in Vir using a covered call strategy, do the following: Selecting the July $22.50 call strikes, fashion a covered call order with a net debit in the $19.25 to $19.75 a share range (net stock price - option premium). This strategy provides downside protection of approximately 15% and 18% of potential upside even if the stock drops a bit over the just less than five month option duration. Basically, a very similar set up to the FLGT trade last week.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long FLGT and VIR.

TAGS: Drug Approvals | Investing | Options | Biotechnology | Healthcare

More from Options

'Exchange' Risk for the Security of This Defensive Fund

Bret Jensen
Mar 19, 2023 7:30 AM EDT

Let's look at this health care exchange-traded fund and how to trade it.

The Frenzy of Options Expiration Day Reminds Us: Time Really Is Money

Bob Lang
Mar 17, 2023 12:57 PM EDT

Let's see why this day sets the table for big volatility.

Let's Step Closer to the Money With This Stock

Paul Price
Mar 15, 2023 7:00 AM EDT

Caleres, despite a little trip down, is among my 'Dandy Dozen' stocks, let's see why.

My Trade Amid SVB's Fall? An 'Insurance Policy' on BofA I Hope Doesn't Pay Off

Bret Jensen
Mar 12, 2023 7:30 AM EDT

I bought a small number of July puts on Bank of America, after the fall of Silicon Valley Bank. Here's why and why I don't necessarily hope it works.

Jobs Data Smells Funny, but Not International Flavors & Fragrances

Paul Price
Mar 10, 2023 7:00 AM EST

At the request of a subscriber, here's my take on IFF and how to play it, and on the jobs numbers that come in Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:28 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    There are exceptions to conventional trading wisdo...
  • 05:43 PM EDT CHRIS VERSACE

    Latest AAP Podcast

    I'm joined by Real Money contributor Peter Tchir a...
  • 08:20 AM EDT PETER TCHIR

    Pre-CPI Thoughts

    I believe the risk to CPI is "asymmetric." It ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login